Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Zogenix Inc. Stories

2014-04-15 16:28:26

SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro(TM) ER on Constitutional grounds. This order will become effective on April 22, 2014. The court decision today supports the...

2014-04-08 20:21:36

SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been...

2014-04-07 16:25:34

Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO, April 7, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by...

2014-04-04 08:25:20

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Today, Health and Human Services (HHS) Secretary Kathleen Sebelius, and U.S. Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg, called for a balanced approach in the fight against prescription drug abuse and preserving the protection of the needs and rights of patients suffering from severe chronic pain. It was an impressive showcase of a unified front and a call for all stakeholders to help at every level. It is vitally important...

2014-04-03 00:22:16

SAN DIEGO, April 2, 2014 /PRNewswire/ -- We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro(TM) ER that has been demonstrated to be false. As informed health care experts and the U.S. Food and Drug Administration have noted for the record, Zohydro ER is no more potent than any other hydrocodone medication available. The facts are clear: Zohydro ER is the same...

2014-03-28 00:23:11

SAN DIEGO, March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication. We believe Governor Patrick's ban on Zohydro(TM) ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief...

2014-01-08 08:24:46

Editor Note: For more information about this release, please scroll to bottom. LONDON, January 8, 2014 /PRNewswire/ -- On Tuesday, January 07, 2014, the US equity market ended on a higher note as the S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index advanced 1.01% to end the day at 644.13. The S&P 500...

2013-07-24 12:29:11

Editor Note: For more information about this release, please scroll to bottom LONDON, July 24, 2013 /PRNewswire/ -- On Tuesday, July 23, 2013, shares in major drug manufacturers ended on a mixed note, tracking the broader market. The major movers in the industry included Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). All these companies are tracked by AAAResearchReports.com. Free technical research reports...

2013-04-10 08:31:49

LONDON, April 10, 2013 /PRNewswire/ -- One of the major trends to emerge in the healthcare industry in the last year has been the expiration of patents on several blockbuster drugs. This had led to increasing competition from generic drug companies such as Actavis Inc. (NYSE: ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue to boost their product pipeline. Major drug manufacturers...

2013-03-01 08:24:24

LONDON, March 1, 2013 /PRNewswire/ -- The Healthcare industry is undergoing a major overhaul after the Supreme Court last year upheld President Obama's Affordable Care Act (ACA). While critics of the healthcare reform say that it increase costs for the healthcare industry, proponents of ACA note that the increase in the number of insured individuals will ultimately benefit the industry. Meanwhile, healthcare companies such as UnitedHealth Group Inc. (NYSE: UNH), Aetna Inc....